We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App





Qiagen and TScan Therapeutics to Jointly Develop T Cell-Based Laboratory Test for COVID-19 Immune Response

By LabMedica International staff writers
Posted on 11 Nov 2020
QIAGEN N.V. More...
(Venlo, Netherlands) and TScan Therapeutics (Waltham, MA, USA) have entered into a research license and option agreement to develop T cell-based laboratory tests for detecting prior exposure to the novel coronavirus, SARS-CoV-2, using discoveries from TScan’s high-throughput TCR/Target discovery platform, T-Scan.

Under the terms of the agreement, QIAGEN secures an option to license the rights and intellectual property for several of TScan’s discovered immunodominant T cell targets, associated sequences and relevant data for the development and commercialization of in vitro diagnostic tests. In advance of exercising its option, QIAGEN will have the right to further evaluate TScan’s discoveries.

The immunodominant targets included in the agreement were identified through the T-Scan TCR/Target discovery platform, which enabled rapid and comprehensive mapping of the specific epitopes in SARS-CoV-2 that are recognized by the CD8+ T cells of patients recovering from COVID-19. Importantly, the study also revealed that patients’ T cells do not cross-react with seasonal coronaviruses that cause the common cold, decreasing the likelihood that a T cell-based diagnostic test would result in false-positive results.

“We are excited to partner with QIAGEN in response to the global COVID-19 pandemic by combining our unique insight into how T cells recognize the novel coronavirus with QIAGEN’s deep expertise in diagnostics,” said Gavin MacBeath, Ph.D., Chief Scientific Officer at TScan. “Current tests for prior exposure to coronavirus rely on the detection of antibodies, which tend to diminish within a couple of months of being infected with the virus. We believe that detecting anti-viral T cells based on our discoveries will provide a more reliable way to determine exposure to SARS-CoV-2 over a much longer period following infection. If the presence of anti-viral T cells can be linked to protection from future infection, a test like this may ultimately provide valuable information on the course of the pandemic and how to return safely to normal life.”

“As a world-wide leader in the development and commercialization of diagnostic products, QIAGEN is an ideal partner to develop T cell-based tests for COVID-19,” said David Southwell, Chief Executive Officer at TScan. “This marks our second collaboration in our efforts to provide tools in the fight against COVID-19 and highlights the urgency for continued innovation for next-generation vaccines, T cell therapeutics and T cell-based diagnostics to address the dire need posed by the COVID-19 pandemic. This collaboration also reinforces the depth of our T-Scan discovery platform, including its broad application in target discovery across oncology, autoimmune disease and infectious disease that can be leveraged in-house or advanced with key partners.”

Related Links:
QIAGEN N.V.
TScan Therapeutics



Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.